Despite the recent developments in understanding the molecular biology of MF and treatment with JAK inhibitors, which have shown significant clinical benefits for the patients, there remains an unmet need for the condition, due to its molecular and clinical heterogeneity with high degrees of variability from patient to patient - Anca Lupu


image by: Tammy Jones

HWN Recommends

Bob: What I Learned on My Journey With Myelofibrosis

In the summer of 1983, I looked like any other graduate student at the University of Georgia. I happened to be a soccer player, and after a game one day, my left abdomen starting hurting. A lot.

After a few visits to local doctors, a hematologist looked at me and said, “You’re only 28. I had thought I would be telling you that you have something like mononucleosis. But you have primary myelofibrosis (MF).”

I was instantly confronted with the fact that how I looked on the outside—in this case, how the hematologist saw me—didn’t match how I felt on the inside. My abdomen hurt (because my spleen was enlarged) and I had brain fog. Those were the first symptoms of my journey with…

read full article


Related Articles

Stay Connected

©2021 | HealthWorldNet, Inc. | 115476

Last Updated : Sunday, August 15, 2021